Biomarin Pharmaceutical Inc at Cowen Health Care Conference (Virtual) Transcript
Good afternoon, and welcome once again to Cowen and Company's 42nd Annual Healthcare Conference. I'm Phil Nadeau, one of the biotech analyst here at Cowen. And it's my pleasure to moderate a fireside chat with J.J. Bienaime, Chairman and CEO of BioMarin. J.J., I'll hand it to you to begin with some opening remarks.
Thank you. Thank you, Phil, for joining us and all of you for joining us today. I would say the financial, commercial and regulatory momentum at BioMarin has never been stronger as we described on our last quarter call with the addition of what is likely to be our largest market opportunity to date, VOXZOGO, for the treatment of achondroplasia. We expect to transition to sustainable GAAP profitability this year.
I would say the combination of VOXZOGO, and our foundational base business is expected to drive double-digit growth this year and beyond. And despite
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
